Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Local Anesthetics: Differential Sensitivity of Nerve Fibers01:24

Local Anesthetics: Differential Sensitivity of Nerve Fibers

Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Participation of private providers in the National TB Programme in South India.

Public health action·2023
Same author

The geographical distribution and socioeconomic risk factors of COVID-19, tuberculosis and leprosy in Fortaleza, Brazil.

BMC infectious diseases·2023
Same author

Determining target populations for leprosy prophylactic interventions: a hotspot analysis in Indonesia.

BMC infectious diseases·2022
Same author

Association of environmental surface contamination with hand hygiene and infections in nursing homes: a prospective cohort study.

Infection prevention in practice·2021
Same author

The effect of a hand hygiene intervention on infections in residents of nursing homes: a cluster randomized controlled trial.

Antimicrobial resistance and infection control·2021
Same author

Development of a TB vaccine trial site in Africa and lessons from the Ebola experience.

BMC public health·2020

Related Experiment Video

Updated: Jul 15, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

Corticosteroids for treating nerve damage in leprosy.

N H J Van Veen1, P G Nicholls, W C S Smith

  • 1Erasmus MC, University Medical Center, Department of Public Health, PO Box 2040, Rotterdam, Netherlands, 3000 CA. n.vanveen@erasmusmc.nl

The Cochrane Database of Systematic Reviews
|April 20, 2007
PubMed
Summary

Corticosteroids do not significantly improve nerve function in leprosy patients long-term. More research is needed to establish the effectiveness of corticosteroids for leprosy nerve damage and explore new therapies.

More Related Videos

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

Corneal Sensitivity Testing Procedure for Ophthalmologic and Optometric Patients
04:00

Corneal Sensitivity Testing Procedure for Ophthalmologic and Optometric Patients

Published on: August 2, 2024

Related Experiment Videos

Last Updated: Jul 15, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

Corneal Sensitivity Testing Procedure for Ophthalmologic and Optometric Patients
04:00

Corneal Sensitivity Testing Procedure for Ophthalmologic and Optometric Patients

Published on: August 2, 2024

Area of Science:

  • Neurology
  • Infectious Diseases
  • Pharmacology

Background:

  • Leprosy frequently causes nerve damage, leading to impairment and disability.
  • Corticosteroids are a common treatment for leprosy-related nerve damage, but their long-term efficacy remains uncertain.

Purpose of the Study:

  • To evaluate the long-term effects of corticosteroids on nerve damage in individuals with leprosy.

Main Methods:

  • Systematic review of randomized and quasi-randomized controlled trials identified through extensive database searches (Cochrane, MEDLINE, EMBASE, CINAHL, LILACS) up to January 2006.
  • Primary outcome: improvement in sensory and motor nerve function at one year.
  • Secondary outcomes included nerve function at two years, pain, tenderness, and adverse events; data were independently extracted and trial quality assessed.

Main Results:

  • Three randomized controlled trials involving 513 participants were included.
  • Two trials comparing prednisolone with placebo showed no significant difference in nerve function improvement at twelve months.
  • A third trial indicated that a 3-month prednisolone course required more additional corticosteroids compared to 5-month regimens for severe reactions; serious adverse events were not significantly more frequent with corticosteroids.

Conclusions:

  • Current evidence from randomized controlled trials does not support a significant long-term benefit of corticosteroids for acute nerve damage in leprosy.
  • Further high-quality randomized controlled trials are necessary to determine the effectiveness of corticosteroids, optimal treatment regimens, and to investigate novel therapeutic approaches for leprosy-induced nerve damage.